| pubmed-article:3848264 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3848264 | lifeskim:mentions | umls-concept:C0025266 | lld:lifeskim |
| pubmed-article:3848264 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3848264 | lifeskim:mentions | umls-concept:C0403823 | lld:lifeskim |
| pubmed-article:3848264 | lifeskim:mentions | umls-concept:C0022478 | lld:lifeskim |
| pubmed-article:3848264 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3848264 | pubmed:dateCreated | 1985-8-22 | lld:pubmed |
| pubmed-article:3848264 | pubmed:abstractText | A randomised group of 75 men with idiopathic oligoasthenozoospermia and asthenozoospermia were subjected to control study with kallikrein. Kallikrein was given to 45 men 600 units daily in a period of 3-6 months. The other group of 30 infertile men was followed during the same period of time. Percentage of motile sperm was significantly improved after 3-6 months treatment with kallikrein. Sperm count and percentage of morphologically normal sperm showed improvement but was not statistically significant. Infertile men with sperm count below 20 X 10(6)/ml had greater improvement in sperm count than men with sperm count over 20 X 10(6)/ml. This study emphasizes that kallikrein is a relatively good drug for restoring sperm motility in idiopathic oligoasthenozoospermia and asthenozoospermia. | lld:pubmed |
| pubmed-article:3848264 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3848264 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3848264 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3848264 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3848264 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3848264 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3848264 | pubmed:issn | 0587-2421 | lld:pubmed |
| pubmed-article:3848264 | pubmed:author | pubmed-author:Sulovi?VV | lld:pubmed |
| pubmed-article:3848264 | pubmed:author | pubmed-author:BilaSS | lld:pubmed |
| pubmed-article:3848264 | pubmed:author | pubmed-author:Ili?VV | lld:pubmed |
| pubmed-article:3848264 | pubmed:author | pubmed-author:Mi?i?SS | lld:pubmed |
| pubmed-article:3848264 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3848264 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:3848264 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3848264 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3848264 | pubmed:pagination | 51-4 | lld:pubmed |
| pubmed-article:3848264 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:3848264 | pubmed:meshHeading | pubmed-meshheading:3848264-... | lld:pubmed |
| pubmed-article:3848264 | pubmed:meshHeading | pubmed-meshheading:3848264-... | lld:pubmed |
| pubmed-article:3848264 | pubmed:meshHeading | pubmed-meshheading:3848264-... | lld:pubmed |
| pubmed-article:3848264 | pubmed:meshHeading | pubmed-meshheading:3848264-... | lld:pubmed |
| pubmed-article:3848264 | pubmed:meshHeading | pubmed-meshheading:3848264-... | lld:pubmed |
| pubmed-article:3848264 | pubmed:meshHeading | pubmed-meshheading:3848264-... | lld:pubmed |
| pubmed-article:3848264 | pubmed:meshHeading | pubmed-meshheading:3848264-... | lld:pubmed |
| pubmed-article:3848264 | pubmed:meshHeading | pubmed-meshheading:3848264-... | lld:pubmed |
| pubmed-article:3848264 | pubmed:meshHeading | pubmed-meshheading:3848264-... | lld:pubmed |
| pubmed-article:3848264 | pubmed:meshHeading | pubmed-meshheading:3848264-... | lld:pubmed |
| pubmed-article:3848264 | pubmed:articleTitle | Treatment of men with oligoasthenozoospermia and asthenozoospermia with kallikrein. | lld:pubmed |
| pubmed-article:3848264 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3848264 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3848264 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
